Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection

Therapeutic Drug Monitoring

Volumn 26, Issue 5, 2004, Pages 516-523

  Alexander, Christopher S ^a,b,c   Montaner, Julio S G ^a,b   Asselin, Jérôme J ^a   Ting, Lillian ^a   McNabb, Kelly ^a   Harris, Marianne ^a   Guillemi, Silvia ^a,b   Richard Harrigan, P ^a,b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

HIV; Lopinavir ritonavir; Reduced sampling models

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; LOPINAVIR; NEVIRAPINE; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; STEADY STATE; TANDEM MASS SPECTROMETRY;

ADULT; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR;

EID: 4744355003     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200410000-00009     Document Type: Article

References (28)

1. Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther. 1998;3:215-220.
2. Gieschke R, Fotteler B, Buss N, et al. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet. 1999;37:75-86.
3. Reijers MH, Weigel HM, Hart AA, et al. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS. 2000;14:59-67.
4. Chan S, Zhang M, Pithavala Y, et al. Potential early predictors of long term virologie response to nelfinavir mesylate (Viracept): plasma drug concentration, baseline viral load and initial 4-week change in viral load [abstract A-11]. In Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998.
5. Hoetelmans RMW, Meenhorst PL, Mulder JW, et al. Plasma concentrations of saquinavir determine HIV-1 RNA response over a 48-week period [abstract 42261]. In Program and Abstracts of the 12th World AIDS Conference (Geneva, Switzerland), 1998.
6. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 2001;15:1089-1095.
7. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
8. Kaletra™ Product Information. Abbott Laboratories, North Chicago, IL; October 2000.
9. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs. 2003;63:769-802.
10. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS. 2000;14: 1333-1339.
11. Pellegrin I, Breilh D, Montestruc F, et al. Virologie response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS. 2002;16:1331-1340.
12. Masquelier B, Breilh D, Neau D, et al. Groupe d' Epidemiologie Clinique du SIDA en Aquitaine. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir- containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2002;46:2926-2932.
13. Murphy RL, Sommadossi JP, Lamson M, et al. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis. 1999;179: 1116-1123.
14. min is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen. J Acquir Immune Defic Syndr. 2002;29:374-377.
15. Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS. 1999;13:2083-2089.
16. Burger D, Boyd M, Duncombe C, et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother. 2003;51:1231-1238.
17. Anderson PL, Brundage RC, Kakuda TN, et al. Indinavir (IDV) maximum plasma concentration predicts CD4+ response in persons with highly suppressed HIV RNA [Abstract 731]. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 2001.
18. Van Heeswijk RP. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther Drug Monit. 2002;24:323-331.
19. Quenouille MH. Problems in plane sampling. Ann Math Statist. 1949;20: 355-375.
20. Gelman A, Carlin JB, Stern HS, et al. Bayesian Data Analysis. New York: Chapman & Hall/CRC, 1995:236.
21. Khanlou H, Graham E, Brill M, et al. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy. AIDS. 2002;16:797-798.
22. Fatkenheuer G, Romer K, Kamps R, et al. Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients. AIDS. 2001;15:2334-2335.
23. Tran JQ, Gerber JG, Kerr BM. Delavirdine: Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet. 2001;40:207-226.
24. Regazzi MB, Villani P, Maserati R, et al. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals. Br J Clin Pharmacol. 1999;47:379-382.
25. Veldkamp AI, van Heeswijk RP, Mulder JW, et al. Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 non-nucleoside reverse transcriptase inhibitor nevirapine. Ther Drug Monit. 2001;23:606-611.
26. min) [Abstact 7.3]. In Program and Abstracts of the 3rd International Workshop on Clinical Pharmacology of HIV Therapy. Washington, DC, April 11-13, 2002.
27. Burger DM, Hugen PWH, Aarnoutse RE, et al. on behalf of the ATHENA Study Group. Treatment failure of Nelfinavir-containing triple therapy can largely be explained by low Nelfinavir plasma concentrations. Ther Drug Monit. 2003;25:73-80.
28. Dieleman JP, Gyssens IC, van der Ende ME, et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS. 1999;13:473-478.